Naylor ML, Yun J, Arnold D. No evidence of disease activity achievement over 4 years of peginterferon beta-1a treatment in newly diagnosed patients with relapsing Multiple Sclerosis: subgroup analyses of ADVANCE/ATTAIN. EAN 2018, poster EPR2116.
Gen-omgevingsinteracties bij ALS: rol van roken, alcohol, BMI en C9orf72-status
mei 2021 | Neuro-musculair